#Cannabis Capital Markets
#Cannabis Capital Markets · page 2
- CBD Market
2022 Will See The Race To The Bottom Replaced By A Healthy Focus On Profitable Business Models
Stenocare CEO Thomas Skovlund Schnegelsberg reflects on 2021 and looks ahead to the challenges and opportunities that lie ahead in 2022 BC: What are the main opportunities and challenges for the European cannabis industry in 2022?
- CBD Market
A Ground-Breaking Year For European Cannabis Mapped Out In BusinessCann’s 2021 Top 10
THIS has been a remarkable year for European cannabis with some significant milestones passed on an increasingly fruitful trek into the post-prohibition era.
- CBD Market
CBD Consumers Want Trusted Brands And High-Quality Products Backed By Regulators and Retailers
In a Q&A with BusinessCann Eoin Keenan, CEO & Co-Founder, Goodrays, says after seven years working in the industry he expects 2022 to be a break-through year BC: What developments should we expect to see in the European cannabis industry in 2022?
- News
Buy-And-Build Cannabis Company Pivots to Adult-Use Opportunities In Its Domestic Market
GERMAN firm SynBiotic has just completed what it calls the ‘most significant merger in the European cannabis sector’ to date, as it considers how best to position itself to capitalise on the incoming recreational opportunity.
- CBD Market
As 2021 US-To-Europe Transactions Pass $600m Are We Witnessing A Second Transatlantic Wave?
IT’S still early days but after a faltering start by its North American neighbours US cannabis companies are now taking tentative steps into Europe.
- Pharmaceutical
‘With Legalisation Gathering Momentum We Are Witnessing The Emergence Of A Global Cannabis Industry’
NEW analysis from Prohibition Partners on the trajectory of the cannabis industry predicts significant global growth over the coming years The ‘The Global Cannabis Report: Second Edition’ estimates 2021 sales of CBD, medical and adult-use cannabis will hit $37.4bn and could rise by 220% to over $105bn by 2026.
- CBD Market
Hemp Pioneer On The $11.2m Sale Of His Business And The Decade’s ‘Most Exciting Industry’
EUROPEAN cannabis industry ‘pioneer’ Daniel Kruse believes that Germany is poised to ‘lead the way for a new global drug policy’.
- Pharmaceutical
London Stock Exchange Cannabis Company Values Down Almost £200m From Early Peaks
THIS has been a transformative year for the European cannabis industry, with growing liberalisation across the continent opening the floodgates for patients and investors alike.
- Pharmaceutical
High-Profile Director Quits Oxford Cannabinoid Technologies Board Following Chairman’s Recent Departure
Oxford Cannabinoid Technologies (OCT) has seen its second senior departure in under a month as it begins to recover from the fallout of a credit deal which breached market rules.
- Pharmaceutical
Work To Start On UK Mainland’s First Commercial Cannabis Cultivation Facility For Over 20 Years
GLASS Pharms has agreed a £22.5m funding deal to build the UK mainland’s first, high-THC, commercial cultivation facility for over 20 years.
- Markets & Stocks
MGC Pharmaceuticals Tells Shareholders Pending Deal Could ‘Transform Finances Overnight’
MGC Pharmaceuticals told shareholders attending its Annual General Meeting (AGM) that it is on track to deliver ‘far and away the best financial performance of the company’ in the coming months.
- Hemp Industry
SynBiotic SE Buys Hemp Pioneer’s Group Of Companies For €11.2m
It is the most significant merger in the European cannabis sector.
